As number of COVID-19 cases in Russia crossed 500,000, the government has rolled out a drug to treat the novel coronavirus even though clinical trials are still underway.
The country's health ministry has approved the use of the anti-viral drug, registered under the name Avifavir, under a special accelerated process.
In a press release, the state financial backer said the drug has been delivered to some hospitals and clinics in the country.
The country's RDIF sovereign wealth fund has a 50 per cent share in a joint venture with the drug's manufacturer ChemRar.
There is currently no vaccine for COVID-19, with human trials of several existing antiviral drugs yet to show efficacy.
So far, the country has 502,436 positive cases and the death toll stands at 6,532.


US military marks 11th successive night of attacks on Iran
Indian opposition disrupts parliament to support student protesters and pressure Modi
Rubio says US still willing to negotiate over Iran crisis
House fire kills 10 in Peru's capital, including five minors
Ukraine will step up counteroffensive actions, Zelenskyy's new top commander says
